Press Releases

Loxo Oncology to Present at Cowen and Company 37th Annual Health Care Conference

STAMFORD, Conn., March 01, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. BilenkerM.D., chief executive officer, will present a corporate overview at the Cowen and Company 37th Annual Health Care Conference in Boston on Wednesday, March 8, 2017 at 10:40AM Eastern Time.

A live broadcast of the presentation will be available at http://ir.loxooncology.com/. An archived replay of the presentation will be available on the company’s website for 30 days following the presentation.

About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.

Contacts for Loxo Oncology, Inc.

Company:
Jacob S. Van Naarden
Chief Business Officer
jake@loxooncology.com

Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
prahmer@troutgroup.com

Media:
Dan Budwick
Pure Communications
973-271-6085
dbudwick@purecommunications.com

Loxo Oncology, Inc.